SCHEMBL3662282

SCHEMBL3662282

CC(C)C(=O)Nc1ccc(C(=O)CN2C(=O)NC(Cc3ccccc3)(c3ccccc3)C2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.53
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 1/20 0.45
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
USP2 O75604 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3662021 0.92 HDAC6 (0.51) HDAC6KMT2AMEN1MAPTPOLB
SCHEMBL3662076 0.87 KMT2A (0.55) HDAC6KMT2AMEN1MAPTPOLB
SCHEMBL3656307 0.86 HDAC6 (0.53) HDAC6KMT2AMEN1MAPTPOLB
SCHEMBL3660718 0.85 MEN1 (0.58) KMT2AMEN1POLB
SCHEMBL4121157 0.82 KMT2A (0.55) HDAC6KMT2AMEN1MAPTALDH1A1
SCHEMBL3659938 0.79 KMT2A (0.61) KMT2AMEN1MAPTPOLBPKM
SCHEMBL3660498 0.78 KMT2A (0.61) KMT2AMEN1MAPTPOLBPKM
SCHEMBL3660710 0.78 KMT2A (0.66) KMT2AMEN1MAPTPOLBPKM
SCHEMBL3659352 0.77 MEN1 (0.56) KMT2AMEN1POLBSMN1; SMN2
SCHEMBL3663347 0.77 KMT2A (0.58) HDAC6KMT2AMEN1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101827840-A Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators NOVARTIS AG 2010-09-08 CN claimed
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP claimed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO claimed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US claimed
CN-101827840-A Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators NOVARTIS AG 2010-09-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 HDAC6 715/4885KMT2A 2020/4885MEN1 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.